Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]
Dynavax received U.S. FDA nod for Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]
U.S. FDA approved Dynavax drugs Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] for the treatment of Hepatitis B.
Company: Dynavax
Specific Treatments: Hepatitis B virus
Therapeutic Areas: Hepatology (Gall Bladder, Pancreatic, Liver), Infections and Infectious Diseases
General Information of Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]
Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
Heplisav-B is specifically indicated for prevention of infection caused by all known subtypes of hepatitis B virus for use in adults 18 years of age and older.
Heplisav-B is supplied as a solution for intramuscular injection. The recommended dose is two doses (0.5 mL each) administered one month apart.
